

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|--|--|
| (51) International Patent Classification ⁶ : C07D 295/08, A61K 31/495, 31/445 | A1 | (11) International Publication Number: WO 97/19068 (43) International Publication Date: 29 May 1997 (29.05.97) |
| (21) International Application Number: PCT/US96/16761 (22) International Filing Date: 18 October 1996 (18.10.96) (30) Priority Data: 60/007,372 17 November 1995 (17.11.95) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ORTWINE, Daniel, Fred [US/US]; 3594 Oak Park Drive, Saline, MI 48176 (US). PURCHASE, Claude, Forsey, Jr. [US/US]; 4961 Ravine Court, Ann Arbor, MI 48105 (US). WHITE, Andrew, David [GB/US]; 10007 Kress, Lakeland, MI 48143 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al. | (81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> | |
| (54) Title: SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES (57) Abstract <p>Sulfonamide compounds are described which are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A (72 kD gelatinase). Also described are methods for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes using the compounds.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Larvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

-1-

SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES

5

FIELD OF THE INVENTION

10 The present invention relates to sulfonamide compounds that inhibit matrix metalloproteinases, pharmaceutical compositions that include these compounds, and pharmaceutical methods of treatment using these compounds.

15

BACKGROUND OF THE INVENTION

20 The novel compounds of the present invention are inhibitors of matrix metalloproteinases, e.g., stromelysin-1 and gelatinase A (72 kDa gelatinase). More particularly, the compounds of the present invention are useful in the treatment of atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal
25 ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, multiple sclerosis, and other autoimmune or inflammatory disorders dependent on the tissue invasion of leukocytes or other activated migrating cells.

30 Stromelysin-1 and gelatinase A are members of the matrix metalloproteinase (MMP) family (Woessner J.F., FASEB J. 1991;5:2145-2154). Other members include fibroblast collagenase, neutrophil collagenase, gelatinase B (92 kDa gelatinase), stromelysin-2,
35 stromelysin-3, matrilysin, collagenase 3 (Freije J.M., Diez-Itza I., Balbin M., Sanchez L.M., Blasco R., Tolivia J., and Lopez-Otin C., J. Biol. Chem., 1994;269:16766-16773), and the newly discovered membrane-associated matrix metalloproteinases (Sato H.,

-2-

Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., and Seiki M., Nature, 1994;370:61-65).

5 The catalytic zinc in matrix metalloproteinases is the focal point for inhibitor design. The modification of substrates by introducing chelating groups has generated potent inhibitors such as peptide hydroxamates and thiol-containing peptides. Peptide hydroxamates and the natural endogenous inhibitors of MMPs (TIMPs) have been used successfully to treat
10 animal models of cancer and inflammation.

The ability of the matrix metalloproteinases to degrade various components of connective tissue makes them potential targets for controlling pathological processes. For example, the rupture of atherosclerotic
15 plaques is the most common event initiating coronary thrombosis. Destabilization and degradation of the extracellular matrix surrounding these plaques by MMPs has been proposed as a cause of plaque fissuring. The shoulders and regions of foam cell accumulation in
20 human atherosclerotic plaques show locally increased expression of gelatinase B, stromelysin-1, and interstitial collagenase. In situ zymography of this tissue revealed increased gelatinolytic and caseinolytic activity (Galla Z.S., Sukhova G.K.,
25 Lark M.W., and Libby P., "Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques", J. Clin. Invest., 1994;94:2494-2503). In addition, high levels of stromelysin RNA message have
30 been found to be localized to individual cells in atherosclerotic plaques removed from heart transplant patients at the time of surgery (Henney A.M., Wakeley P.R., Davies M.J., Foster K., Hembry R., Murphy G., and Humphries S., "Localization of
35 stromelysin gene expression in atherosclerotic plaques

-3-

by in situ hybridization", Proc. Nat'l. Acad. Sci., 1991;88:8154-8158).

Inhibitors of matrix metalloproteinases will have utility in treating degenerative aortic disease associated with thinning of the medial aortic wall. Increased levels of the proteolytic activities of MMPs have been identified in patients with aortic aneurisms and aortic stenosis (Vine N. and Powell J.T., "Metalloproteinases in degenerative aortic diseases", Clin. Sci., 1991;81:233-239).

Heart failure arises from a variety of diverse etiologies, but a common characteristic is cardiac dilation which has been identified as an independent risk factor for mortality (Lee T.H., Hamilton M.A., Stevenson L.W., Moriguchi J.D., Fonarow G.C., Child J.S., Laks H., and Walden J.A., "Impact of left ventricular size on the survival in advanced heart failure", Am. J. Cardiol., 1993;72:672-676). This remodeling of the failing heart appears to involve the breakdown of extracellular matrix. Matrix metalloproteinases are increased in patients with both idiopathic and ischemic heart failure (Reddy H.K., Tyagi S.C., Tjaha I.E., Voelker D.J., Campbell S.E., and Weber K.T., "Activated myocardial collagenase in idiopathic dilated cardiomyopathy", Clin. Res., 1993;41:660A; Tyagi S.C., Reddy H.K., Voelker D., Tjara I.E., and Weber K.T., "Myocardial collagenase in failing human heart", Clin. Res., 1993;41:681A). Animal models of heart failure have shown that the induction of gelatinase is important in cardiac dilation (Armstrong P.W., Moe G.W., Howard R.J., Grima E.A., and Cruz T.F., "Structural remodeling in heart failure: gelatinase induction", Can. J. Cardiol., 1994;10:214-220), and cardiac dilation precedes profound deficits in cardiac function (Sabbah H.N., Kono T., Stein P.D., Mancini G.B., and

-4-

Goldstein S., "Left ventricular shape changes during the course of evolving heart failure", Am. J. Physiol., 1992;263:H266-H270).

5 Neointimal proliferation, leading to restenosis, frequently develops after coronary angioplasty. The migration of vascular smooth muscle cells (VSMCs) from the tunica media to the neointima is a key event in the development and progression of many vascular diseases and a highly predictable consequence of mechanical
10 injury to the blood vessel (Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., and Reidy M., "Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat", Circulation Research, 1994;75:539-545). Northern blotting and
15 zymographic analyses indicated that gelatinase A was the principal MMP expressed and excreted by these cells. Further, antisera capable of selectively neutralizing gelatinase A activity also inhibited VSMC migration across basement membrane barrier. After
20 injury to the vessel, gelatinase A activity increased more than 20-fold as VSCMs underwent the transition from a quiescent state to a proliferating, motile phenotype (Pauly R.R., Passaniti A., Bilato C., Monticone R., Cheng L., Papadopoulos N., Gluzband Y.A.,
25 Smith L., Weinstein C., Lakatta E., and Crow M.T., "Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation", Circulation Research, 1994;75:41-54).
30 Collagenase and stromelysin activities have been demonstrated in fibroblasts isolated from inflamed gingiva (Uitto V.J., Applegren R., and Robinson P.J., "Collagenase and neutral metalloproteinase activity in extracts from inflamed human gingiva", J. Periodontal Res., 1981;16:417-424), and enzyme levels have been
35 correlated to the severity of gum disease

-5-

(Overall C.M., Wiebkin O.W., and Thonard J.C.,
"Demonstrations of tissue collagenase activity in vivo
and its relationship to inflammation severity in human
gingiva", J. Periodontal Res., 1987;22:81-88).

5 Proteolytic degradation of extracellular matrix has
been observed in corneal ulceration following alkali
burns (Brown S.I., Weller C.A., and Wasserman H.E.,
"Collagenolytic activity of alkali burned corneas",
10 Arch. Ophthalmol., 1969;81:370-373). Thiol-containing
peptides inhibit the collagenase isolated from alkali-
burned rabbit corneas (Burns F.R., Stack M.S.,
Gray R.D., and Paterson C.A., Invest. Opththamol.,
1989;30:1569-1575).

15 Stromelysin is produced by basal keratinocytes in
a variety of chronic ulcers (Saarialho-Kere U.K.,
Ulpu K., Pentland A.P., Birkedal-Hansen H., Parks W.C.,
Welgus H.G., "Distinct populations of basal
keratinocytes express stromelysin-1 and stromelysin-2
in chronic wounds", J. Clin. Invest., 1994;94:79-88).

20 Stromelysin-1 mRNA and protein were detected in
basal keratinocytes adjacent to but distal from the
wound edge in what probably represents the sites of
proliferating epidermis. Stromelysin-1 may thus
prevent the epidermis from healing.

25 Davies, et al., (Cancer Res., 1993;53:2087-2091)
reported that a peptide hydroxamate, BB-94, decreased
the tumor burden and prolonged the survival of mice
bearing human ovarian carcinoma xenografts. A peptide
of the conserved MMP propeptide sequence was a weak
30 inhibitor of gelatinase A and inhibited human tumor
cell invasion through a layer of reconstituted basement
membrane (Melchiori A., Albili A., Ray J.M., and
Stetler-Stevenson W.G., Cancer Res., 1992;52:2353-
2356), and the natural tissue inhibitor of
35 metalloproteinase-2 (TIMP-2) also showed blockage of
tumor cell invasion in in vitro models (DeClerck Y.A.,

-6-

Perez N., Shimada H., Boone T.C., Langley K.E., and Taylor S.M., Cancer Res., 1992;52:701-708). Studies of human cancers have shown that gelatinase A is activated on the invasive tumor cell surface (Strongin A.Y.,
5 Marmer B.L., Grant G.A., and Goldberg G.I., J. Biol Chem., 1993;268:14033-14039) and is retained there through interaction with a receptor-like molecule (Monksky W.L., Kelly T., Lin C.-Y., Yeh Y., Stetler-Stevenson W.G., Mueller S.C., and Chen W.-T.,
10 Cancer Res., 1993;53:3159-3164).

Inhibitors of MMPs have shown activity in models of tumor angiogenesis (Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., Brown P.D., and Giavazzi R., Journal of the National
15 Cancer Institute, 1995;87:293; and Benelli R., Adatia R., Ensoli B., Stetler-Stevenson W.G., Santi L., and Albini A., Oncology Research, 1994;6:251-257).

Several investigators have demonstrated consistent elevation of stromelysin and collagenase in synovial
20 fluids from rheumatoid and osteoarthritis patients as compared to controls (Walakovits L.A., Moore V.L., Bhardwaj N., Gallick G.S., and Lark M.W., "Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and post-traumatic
25 knee injury", Arthritis Rheum., 1992;35:35-42; Zafarullah M., Pelletier J.P., Cloutier J.M., and Marcel-Pelletier J., "Elevated metalloproteinases and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia", J. Rheumatol., 1993;20:693-
30 697). TIMP-1 and TIMP-2 prevented the formation of collagen fragments, but not proteoglycan fragments, from the degradation of both the bovine nasal and pig articular cartilage models for arthritis, while a synthetic peptide hydroxamate could prevent the
35 formation of both fragments (Andrews H.J., Plumpton T.A., Harper G.P., and Cawston T.E., Agents

-7-

Actions, 1992;37:147-154; Ellis A.J., Curry V.A., Powell E.K., and Cawston T.E., Biochem. Biophys. Res. Commun., 1994;201:94-101).

5 Gijbels, et al., (J. Clin. Invest., 1994;94:2177-2182) recently described a peptide hydroxamate, GM6001, that suppressed the development or reversed the clinical expression of experimental allergic encephalomyelitis (EAE) in a dose dependent manner, suggesting the use of MMP inhibitors in the treatment
10 of autoimmune inflammatory disorders such as multiple sclerosis.

 A recent study by Madri has elucidated the role of gelatinase A in the extravasation of T-cells from the blood stream during inflammation (Ramanic A.M. and
15 Madri J.A., "The Induction of 72-kD Gelatinase in T Cells upon Adhesion to Endothelial Cells is VCAM-1 Dependent", J. Cell Biology, 1994;125:1165-1178). This transmigration past the endothelial cell layer is coordinated with the induction of gelatinase A and is
20 mediated by binding to the vascular cell adhesion molecule-1 (VCAM-1). Once the barrier is compromised, edema and inflammation are produced in the CNS. Leukocytic migration across the blood-brain barrier is known to be associated with the inflammatory response
25 in EAE. Inhibition of the metalloproteinase gelatinase A would block the degradation of extracellular matrix by activated T-cells that is necessary for CNS penetration.


 These studies provided the basis for the belief
30 that an inhibitor of stromelysin-1 and/or gelatinase A will treat diseases involving disruption of extracellular matrix resulting in inflammation due to lymphocytic infiltration, inappropriate migration of metastatic or activated cells, or loss of structural
35 integrity necessary for organ function.

-8-

We have identified a series of sulfonamide compounds that are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A, and thus useful as agents for the treatment of multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

SUMMARY OF THE INVENTION

The present invention provides compounds of the Formula I



wherein:

- Ar is selected from phenyl;
- phenyl substituted with alkyl, $-\text{NO}_2$, halogen, $-\text{OR}^5$, $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{SO}_3\text{R}^5$, $-\text{CHO}$, $-\text{COR}^5$, $-\text{CONHR}^5$, $-\text{NHR}^5$, or $-\text{NHCOR}^5$;
- heteroaryl; or
- 2-naphthyl;
- R^1 is hydrogen, methyl, $-\text{NO}_2$, $-\text{Cl}$, $-\text{NH}_2$, $-\text{NHCO}_2\text{CH}_3$, $-\text{OH}$, or $-\text{CO}_2\text{H}$;
- R^2 , R^3 , and R^a are the same or different and are independently selected from hydrogen, alkyl, $-(\text{CH}_2)_v\text{-aryl}$, $-(\text{CH}_2)_v\text{-heteroaryl}$, $-(\text{CH}_2)_v\text{-cycloalkyl}$, $-(\text{CH}_2)_p\text{-X-(CH}_2)_q\text{-aryl}$,

-9-

$-(CH_2)_p-X-(CH_2)_q$ -heteroaryl, $-(CH_2)_tNR^{6a}$,
 $-(CH_2)_vR^7$, $-(CH_2)_vCO_2R^5$, $-(CH_2)_vCONR^{6a}$, or
 $-(CH_2)_vSR^5$;

m is zero or 1;

5 Y is CH or N; provided that when m = 1, Y does not = N;

z is zero or 1;

W is $-CHR^8$;

n is zero or 1;

R^4 is $-OH$, $-NR^{6a}$, or $-NHOR^9$;

10 R^5 is hydrogen or alkyl;

v is 1 to 5;

X is O or S;

p and q are independently 1 to 5, provided that p+q is
not greater than 5;

15 t is 1 to 9;

R^6 and R^{6a} are each the same or different and are
hydrogen or alkyl;

R^7 is 1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl, or
1,3-dihydro-1,3-dioxo-benzo[f]isoindol-2-yl;

20 R^8 is hydrogen or alkyl; and

R^9 is hydrogen, alkyl, or benzyl; or

a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the present invention
provides compounds of Formula I wherein:

25 Ar is phenyl;

m is 0 or 1;

Y is CH or N;

R^1 is hydrogen;

Z is zero;

30 R^2 is hydrogen or alkyl;

R^3 is hydrogen, alkyl, $-(CH_2)_n$ -aryl, or
 $-(CH_2)_n$ -heteroaryl;

R^4 is $-OH$ or $-NHOH$;

n is 0 or 1; and

35 W is $-CH_2-$; or

a pharmaceutically acceptable salt thereof.

-10-

In other preferred embodiments of the present invention relating to the compounds of Formula I, Z is zero, or Ar is phenyl, or Y is C, or m is zero, or R² is hydrogen, or R¹ is hydrogen, or n is zero, or R⁴ is -OH, and pharmaceutically acceptable salts of these
5 compounds provided that when m = 1, Y does not = N.

In a most preferred embodiment, the compounds of Formula I are:

[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonyl-
10 amino]-acetic acid;
N-Hydroxy-2-[4-(4-phenyl-piperidin-1-yl)-
benzenesulfonylamino]-acetamide;
3-[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonyl-
amino]-propionic acid;
15 (R)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-
benzenesulfonylamino]-pentanoic acid;
(S)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-
benzenesulfonylamino]-pentanoic acid;
(S)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-
20 benzenesulfonylamino]-propionic acid;
(R)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-
benzenesulfonylamino]-propionic acid;
(S)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-
yl)-benzenesulfonylamino]-propionic acid;
25 (±)-5-Phenyl-2-[4-(4-phenyl-piperidin-1-
yl)-benzenesulfonylamino]-pentanoic acid;
[4-(4-Phenyl-piperazin-1-yl)-benzenesulfonyl-
amino]-acetic acid;
{Isobutyl-[4-(4-phenyl-piperidin-1-yl)-benzene-
30 sulfonyl]amino}-acetic acid;
(S)-4-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-
benzenesulfonylamino]-butyric acid;
(R)-2-[4-(4-Phenyl-piperidin-1-yl)-benzene-
sulfonylamino]-3-tritylsulfanyl-propionic acid sodium
35 salt;

-11-

(R)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid, disodium salt, monohydrate;

5 (S)-2-[4-[-4-(4-Hydroxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid;

(S)-2-[4-[-4-(4-Chloro-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid, hydrochloride;

10 (R)-3-Mercapto-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid, trifluoroacetic acid salt;

(S)-2-[4-(4-Benzyl-piperidin-1-yl)-benzenesulfonylamino]-3-phenyl-propionic acid;

15 (S)-3-(4-Benzyloxy-phenyl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;

(S)-3-(4-Hydroxy-phenyl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;

(S)-3-Phenyl-2-[4-(4-phenyl-piperazin-1-yl)-benzenesulfonylamino]-propionic acid;

20 (S)-2-[4-[-4-(3-Methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid;

(S)-2-[4-[-4-(3-Hydroxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid hydrobromide; and

25 (S)-2-[4-[-4-(4-Methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid.

30 The present invention also provides a method of inhibiting a matrix metalloproteinase, the method comprising administering to a patient in need of matrix metalloproteinase inhibition a matrix metalloproteinase inhibiting amount of a compound of Formula I.

35 In a preferred embodiment, the matrix metalloproteinase is stromelysin-1 or gelatinase-A.

-12-

In another embodiment, the present invention provides a method of preventing atherosclerotic plaque rupture comprising administering to a patient suffering from an atherosclerotic plaque a therapeutically effective amount of a compound of Formula I.

In another embodiment, the present invention provides a method of inhibiting aortic aneurism comprising administering to a patient having an aortic aneurism a therapeutically effective amount of a compound of Formula I.

In another embodiment, the present invention provides a method of preventing restenosis comprising administering to a patient following balloon angioplasty, graft or shunt implantation, or atherectomy, a therapeutically effective amount of a compound of Formula I.

In another embodiment, the present invention provides a method of treating periodontal disease comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

In another embodiment, the present invention provides a method of treating burns comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

In another embodiment, the present invention provides a method of treating decubital ulcers comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

In another embodiment, the present invention provides a method of treating chronic ulcers or wounds comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

-13-

5 In another embodiment, the present invention provides a method of treating cancer comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

10 In another embodiment, the present invention provides a method of treating multiple sclerosis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

15 In another embodiment, the present invention provides a method of treating arthritis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.


20 In another embodiment, the present invention provides a method of treating autoimmune or inflammatory disorder dependent upon tissue invasion by leukocytes comprising administering to a patient suffering from an autoimmune or inflammatory disorder dependent upon tissue invasion by leukocytes a therapeutically effective amount of a compound of Formula I.

25 In another embodiment, the present invention provides a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.

30 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds having the Formula I

-14-



5

wherein:

Ar is selected from phenyl;

phenyl substituted with alkyl, $-\text{NO}_2$, halogen, $-\text{OR}^5$,
 $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{SO}_3\text{R}^5$, $-\text{CHO}$, $-\text{COR}^5$, $-\text{CONHR}^5$, $-\text{NHR}^5$,
 10 or $-\text{NHCOR}^5$;

heteroaryl; or

2-naphthyl;

R^1 is hydrogen, methyl, $-\text{NO}_2$, $-\text{Cl}$, $-\text{NH}_2$, $-\text{NHCO}_2\text{CH}_3$,
 $-\text{OH}$, or $-\text{CO}_2\text{H}$;

15 R^2 and R^3 are the same or different and are
 independently selected from hydrogen, alkyl,
 $-(\text{CH}_2)_v\text{-aryl}$, $-(\text{CH}_2)_v\text{-heteroaryl}$,
 $-(\text{CH}_2)_v\text{-cycloalkyl}$, $-(\text{CH}_2)_p\text{-X-(CH}_2)_q\text{-aryl}$,
 $-(\text{CH}_2)_p\text{-X-(CH}_2)_q\text{-heteroaryl}$, $-(\text{CH}_2)_t\text{NR}^6\text{R}^{6a}$,
 20 $-(\text{CH}_2)_v\text{R}^7$, $-(\text{CH}_2)_v\text{CO}_2\text{R}^5$, $-(\text{CH}_2)_v\text{CONR}^6\text{R}^{6a}$, or
 $-(\text{CH}_2)_v\text{SR}^5$;

m is zero or 1;

Y is CH or N; provided that when $m = 1$, Y does not = N;

z is zero or 1;

25 W is $-\text{CHR}^8$;

n is zero or 1;

R^4 is $-\text{OH}$, $-\text{NR}^6\text{R}^{6a}$, or $-\text{NHR}^9$;

R^5 is hydrogen or alkyl;

v is 1 to 5;

30 X is O or S;

p and q are independently 1 to 5, provided that $p+q$ is
 not greater than 5;

t is 1 to 9;

35 R^6 and R^{6a} are each the same or different and are
 hydrogen or alkyl;

-15-

R⁷ is 1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl, or
1,3-dihydro-1,3-dioxo-benzo[f]isoindol-2-yl;

R⁸ is hydrogen or alkyl; and

R⁹ is hydrogen, alkyl, or benzyl; or

5 a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the present invention
provides compounds of Formula I wherein:

Ar is phenyl;

m is 0 or 1;

10 Y is CH or N;

R¹ is hydrogen;

Z is zero;

R² is hydrogen or alkyl;

R³ is hydrogen, alkyl, -(CH₂)_n-aryl, or

15 -(CH₂)_n-heteroaryl;

R⁴ is -OH or -NHOH;

n is 0 or 1; and

W is -CH₂-; or

a pharmaceutically acceptable salt thereof, provided

20 that when m = 1, Y does not = N.

The term "alkyl" means a straight or branched
chain hydrocarbon radical having from 1 to 8 carbon
atoms. Representative examples of alkyl groups
include, but are not limited to, methyl, ethyl,
25 n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl,
isobutyl, n-pentyl, n-hexyl, n-heptyl and n-octyl.

The term "alkoxy" and "thioalkoxy" mean O-alkyl or
S-alkyl having from 1 to 6 carbon atoms. Examples of
alkoxy groups include, but are not limited to, methoxy,
30 ethoxy, propoxy, isopropoxy, and butoxy.

The term "cycloalkyl" means a saturated
hydrocarbon ring having 3 to 8 carbon atoms. Examples
of cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
35 cycloheptyl, and cyclooctyl.

-16-

The term "aryl" means an aromatic radical. For example, the aryl group can be a phenyl group, or a phenyl group substituted with 1 to 4 substituents (phenyl is abbreviated "Ph"). The substituents can be the same or different and can be selected from alkyl, alkoxy, thioalkoxy, hydroxy, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, -NO₂, -CN, -CO₂H, -CO₂alkyl, -SO₃H, -CHO, -COalkyl, -CONH₂, -CONH-alkyl, -CONHR⁵, -CON(alkyl)₂, -(CH₂)_n-NH₂, where n is 1 to 5, -(CH₂)_n-NH-alkyl, -NHR⁵, or -NHCOR⁵.

The term "heteroaryl" means an aromatic compound that includes one or more heteroatom. Examples of heteroatoms include O, S, and N. Examples of heteroaryl groups are 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 3- or 4-pyridinyl, 2-pyrazinyl, 1H-indol-6-yl, 1H-indol-5-yl, 1H-benzimidazol-5-yl, or 1H-benzimidazol-6-yl.

The term "halogen" means fluorine, chlorine, bromine, or iodine.

Some of the compounds of Formula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate,

-17-

chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977;66:1).

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloro-procaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M., et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977;66:1).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form

-18-

may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R or S configuration. The present invention includes all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Additionally, the compounds of the present invention may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.

Also provided by the present invention is a method of inhibiting a matrix metalloproteinase, the method comprising administering to a patient in need of matrix metalloproteinase inhibition a matrix metalloproteinase inhibiting amount of a compound of Formula I. In a preferred embodiment, the matrix metalloproteinase is stromelysin-1 or gelatinase-A.

The term "patient" means humans and other animals.

A patient in need of matrix metalloproteinase inhibition is a patient who may suffer from atherosclerotic plaque rupture or restenosis, or a patient who suffers from aortic aneurism, periodontal disease, burns, decubital ulcers, chronic ulcers or

-19-

wounds, cancer, arthritis, multiple sclerosis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.

5 Also provided by the present invention is a method of preventing atherosclerotic plaque rupture comprising administering to a patient suffering from an atherosclerotic plaque a therapeutically effective amount of a compound of Formula I.

10 Also provided by the present invention is a method of inhibiting aortic aneurism comprising administering to a patient having an aortic aneurism a therapeutically effective amount of a compound of Formula I.

15 Also provided by the present invention is a method of preventing restenosis comprising administering to a patient following balloon angioplasty, graft or shunt implantation or atherectomy, a therapeutically effective amount of a compound of Formula.

20 Also provided by the present invention is a method of treating periodontal disease comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

25 Also provided by the present invention is a method of treating burns comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

30 Also provided by the present invention is a method of treating decubital ulcers comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

35 Also provided by the present invention is a method of treating chronic ulcers or wounds comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

-20-

Also provided by the present invention is a method of treating cancer metastasis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

5 Also provided by the present invention is a method of treating arthritis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

10 Also provided by the present invention is a method of treating multiple sclerosis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Formula I.

15 Also provided by the present invention is a method of treating an autoimmune or inflammatory disorder dependent upon tissue invasion by leukocytes comprising administering to a patient suffering from an autoimmune or inflammatory disorder dependent upon tissue invasion by leukocytes a therapeutically effective amount of a compound of Formula I.

20 The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly,
25 intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered
30 transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.

35 For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically

-21-

acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or
5 more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

10 In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and
15 size desired.

The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin,
20 dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier
25 providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as
30 solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The
35 molten homogenous mixture is then poured into

-22-

convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water
5 propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water
10 and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or
15 synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to
20 liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural
25 sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate
30 quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule,
35 tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

-23-

5 The quantity of active component in a unit dose preparation may be varied or adjusted from 1 mg to 1000 mg, preferably 10 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

10 In therapeutic use as agents for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer, multiple sclerosis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes, the compounds utilized in the pharmaceutical method of
15 this invention are administered at the initial dosage of about 1 mg to about 100 mg per kilogram daily. A daily dose range of about 25 mg to about 75 mg per kilogram is preferred. The dosages, however, may be varied depending upon the requirements of the patient,
20 the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of
25 the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

30 The following examples illustrate particular embodiments of the invention and are not intended to limit the specification, including the claims, in any way.

-24-

EXAMPLES


A compound of Formula I can be made by the general route, as set forth in Scheme I below.

With reference to Scheme I, a compound of
5 Formula II is reacted with a compound of Formula III
(commercially available from Sigma Chemical Company,
St. Louis, Missouri, or can be synthesized according to
Schemes V and VI) in the presence of a suitable base
such as triethylamine, sodium carbonate or potassium
10 carbonate in a suitable solvent such as water,
methanol, tetrahydrofuran, or some combination thereof,
at temperatures between 0°C and 50°C to obtain a
compound of Formula IV. The compound of Formula IV is
then reacted with a compound of Formula V in the
15 presence of an excess of a suitable base such as sodium
carbonate or potassium carbonate in a suitable solvent
such as dimethylsulfoxide (DMSO) or dimethylformamide
(DMF) at temperatures between 25°C and 180°C to obtain
a compound of Formula Ia, wherein the variables are
20 defined as above, except that $z = 0$ and $R^4 = OH$.

Specific compounds of the present invention can be prepared by various routes, all of which are well known in the art.

-25-

SCHEME I



-26-

Compounds of Formula I wherein $z = n = 0$, R^1 and R^2 are hydrogen, $Y = CH$, $R^4 = OH$, and Ar, m and R^3 are as defined in Formula I, can be prepared according to the sequence described in Scheme II below.

5 With regard to Scheme II, the halide (1), wherein halo is defined as iodine, bromine or chlorine, is reacted with a suitable metallating agent (M), such as an alkyl lithium, for example, n-butyl lithium, sec-butyl lithium, or tert-butyl lithium, or magnesium
10 metal, in a suitable solvent such as tetrahydrofuran (THF) or diethyl ether (Et_2O) at temperatures between $-80^\circ C$ and $60^\circ C$, followed by 1-(phenylmethyl)-4-piperidinone at temperatures between $-80^\circ C$ and $25^\circ C$ to obtain the 4-piperidinol (2). The 4-piperidinol (2) is
15 dehydrated by stirring in a suitable solvent such as acetic acid (AcOH) with a strong acid catalyst such as concentrated hydrochloric acid (HCl) at temperatures between $0^\circ C$ and reflux to obtain the 1,2,5,6-tetrahydropyridine (3) as an acid salt. The 1,2,5,6-
20 tetrahydropyridine (3) is reduced by catalytic reduction using a suitable catalyst such as 10% palladium on carbon (Pd/C) and hydrogen gas (H_2) at pressures between 10 p.s.i. and 100 p.s.i. in a suitable solvent such as absolute ethanol, acetic acid,
25 or tetrahydrofuran to yield the piperidine hydrochloride (4).

 The sulfonamide (6) wherein R^3 is as defined in Formula I, may be prepared by reacting the amino acid
30 (5) which is commercially available from a variety of vendors, e.g., Sigma Chemical Company, St. Louis, Missouri, or synthesized by standard methods well known in the art, (set forth in Schemes V & VI below) with 4-fluoro-benzenesulfonyl chloride in the presence of a suitable base such as triethylamine, sodium carbonate
35 (Na_2CO_3) or potassium carbonate in a suitable solvent


-27-

such as water, methanol, tetrahydrofuran, at temperatures between 0°C and 50°C.

5 The piperidine hydrochloride (4) is reacted with the sulfonamide (6) in the presence of an excess of a suitable base such as sodium carbonate or potassium carbonate in a suitable solvent such as dimethylsulfoxide or dimethylformamide at temperatures between 25°C and 180°C to obtain the (sulfonylamino)-carboxylic acid (7).

-28-

SCHEME II




-29-

Compounds of Formula I wherein $z = n = 0$, R^1 and R^2 are hydrogen, $Y = CH$, $R^4 = NHOR^9$ or NR^{6a} , and Ar, m and R^3 are as defined in Formula I, can be prepared according to the sequence described in Scheme III.

5 With regard to Scheme III, the (sulfonylamino)-carboxylic acid (7) can be reacted with a suitable O-substituted hydroxylamine hydrochloride of the formula $H_2NOR^9 \cdot HCl$ in the presence of a suitable base such as triethylamine (Et_3N) or N,N-diisopropyl-N-ethylamine and a suitable coupling agent such as 1,1'-carbonyldiimidazole (CDI) or N,N'-dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzo-triazole (HOBT) in a suitable solvent such as tetrahydrofuran (THF), dichloromethane, or N,N-dimethyl-formamide (DMF) at temperatures between $0^\circ C$ and $100^\circ C$ to yield the O-substituted hydroxamic acid (8). When R^9 is defined as benzyl ($R^9 = CH_2Ph$), the O-substituted-hydroxamic acid (8) can be reduced to yield the hydroxamic acid (9) by catalytic reduction using hydrogen gas at pressures between 10 p.s.i. and 100 p.s.i. and a suitable catalyst such as 5% or 10% palladium on barium sulfate in a suitable solvent such as THF or ethanol. Alternatively, the (sulfonylamino)-carboxylic acid (7) can be reacted with various amines of the formula $R^{6a}NH$ in the presence of a suitable coupling agent such as 1,1'-carbonyldiimidazole (CDI) or N,N'-dicyclohexylcarbodiimide (DCC) and 1-hydroxy-benzotriazole (HOBT) in a suitable solvent such as tetrahydrofuran, dichloromethane, or N,N-dimethyl-formamide at temperatures between $0^\circ C$ and $100^\circ C$ to yield the (sulfonylamino)-carboxamides (10).

-30-

SCHEME III



-31-

Compounds of Formula I wherein $z = m = n = 0$, R^1 and R^2 are hydrogen, $Y = N$, and Ar, R^3 , and R^4 , are as defined in Formula I, can be synthesized according to the sequence described in Scheme IV below.


5 With regard to Scheme IV, the amine (11) is reacted with bis(2-chloroethyl)amine hydrochloride of the formula $HN(CH_2CH_2Cl)_2 \cdot HCl$, in a suitable solvent such as chlorobenzene, at temperatures between 25°C and 180°C to yield the piperazine hydrochloride (12). The
10 piperazine hydrochloride (12) is reacted with the sulfonamide (6) in a manner similar to that previously described for compound (7) to obtain the corresponding piperazine-carboxylic acid (13). The piperazine-carboxylic acid (13) can be reacted with a suitable
15 O-substituted hydroxylamine hydrochloride of the formula $H_2NOR^9 \cdot HCl$ in the presence of a suitable base such as triethylamine (Et_3N) or N,N-diisopropyl-N-ethylamine and a suitable coupling agent such as 1,1'-carbonyldi-imidazole (CDI) or N,N'-dicyclohexyl-carbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT) in
20 a suitable solvent such as tetrahydrofuran (THF), dichloromethane, or N,N-dimethylformamide (DMF) at temperatures between 0°C and 100°C to yield the O-substituted-hydroxamic acid (14). Alternatively, the
25 piperazine-carboxylic acid (13) can be converted to the free hydroxamic acid (15) by first reacting with a suitable activating agent such as isobutyl chloroformate of formula $(CH_3)_2CHCH_2COCl$ in the presence of a suitable base such as triethylamine or
30 N,N-diisopropyl-N-ethylamine in a suitable solvent such as dichloromethane or tetrahydrofuran at temperatures between -78°C and +25°C followed by a suitable O-substituted-hydroxylamine such as O-(tri-methylsilyl)-hydroxylamine of formula $H_2NOSi(CH_3)_3$
35 (TMSONH₂) or O-(tert-butyldimethylsilyl)-hydroxylamine of formula $H_2NOSi(CH_3)_2C(CH_3)_3$ and then quenching the

-32-

reaction with aqueous acid. Alternatively, the piperazine-carboxylic acid (13) can be reacted with various amines of the formula $\text{HNR}^6\text{R}^{6a}$ in the presence of a suitable coupling agent such as 1,1'-carbonyldiimidazole (CDI) or N,N'-dicyclohexylcarbodiimide (DCC) and 1-hydroxy-benzotriazole (HOBT) in a suitable solvent such as tetrahydrofuran, dichloro-methane, or N,N-dimethyl-formamide at temperatures between 0°C and 100°C to yield the piperazine-carboxamides (16).

- 33 -

SCHEME IV



-34-


Compounds of Formula I wherein $z = 0$, $n = 1$, R^1 is hydrogen, and Ar, Y, R^2 , R^3 , R^4 , and R^8 are as defined in Formula I can be prepared as set forth in Scheme V below.

5 With regard to Scheme V, an aldehyde (17) is reacted with trimethylphosphono-acetate of formula $(CH_3O)_2P(O)CH_2CO_2CH_3$ in the presence of a suitable base such as sodium hydride or lithium diisopropylamide (LDA) in a suitable solvent such as tetrahydrofuran at
10 temperatures between $-78^\circ C$ and $+60^\circ C$ to yield the unsaturated ester (18). The unsaturated ester (18) is reacted with lithium (R)-(+)-N-benzyl-N- α -methylbenzylamine, prepared in situ by a slow addition of n-butyl lithium to (R)-(+)-N-benzyl-N- α -
15 methylbenzylamine, in a suitable solvent such as tetrahydrofuran at $-78^\circ C$ followed by the addition of R^3 -halo wherein halo is defined as chlorine, bromine, or iodine, and R^3 is as defined in Formula I, and allowing the temperature to slowly warm from $-78^\circ C$ to
20 $+25^\circ C$ overnight to yield the amino ester (19). (The * designates a chiral carbon.) The diastereomers of the amino ester (19) can be separated by column chromatography. The complimentary diastereomer of the amino ester (19) can be prepared by following the
25 procedure described previously and substituting (S)-(-)-N-benzyl-N- α -methylbenzylamine for (R)-(+)-N-benzyl-N- α -methylbenzylamine. The single stereoisomers of amino ester (19) can be reduced separately by reacting with hydrogen gas in the
30 presence of a suitable catalyst such as 5% to 30% palladium on carbon in a suitable solvent such as tetrahydrofuran, acetic acid, methanol, or mixtures thereof at pressures between atmospheric and 100 p.s.i. and temperatures between $25^\circ C$ and $100^\circ C$ to yield the
35 amino ester (20). The amino ester (20) is then reacted in a suitable aqueous acid mixture such as 6 M

-35-


hydrochloric acid at temperatures between 25°C and reflux to yield the amino acid hydrochloride (21). Alternatively, the amino ester (20) can be reacted with an alkyl halide of formula R^2 -halo, wherein R^2 is as defined in Formula I and halo is defined as chlorine, bromine, or iodine, in the presence of a suitable base such as triethylamine or N,N-diisopropyl-N-ethylamine in a solvent such as diethyl ether or tetrahydrofuran at temperatures between 0°C and 50°C followed by conversion of the free amino ester to the amino ester hydrochloride (22). The amino ester hydrochloride (22) is then reacted in a suitable aqueous acid mixture such as 6 M hydrochloric acid following the procedure described above to yield the amino acid hydrochloride (23). When in the procedure described by Scheme II, the amino acid hydrochlorides (21) or (23) are substituted for the amino acid (5) and reacted with 4-fluoro-benzenesulfonyl chloride, the sulfonamides (24) and (25) can be prepared, respectively. When in the procedures described for Schemes II and IV the sulfonamides (24) or (25) are substituted for the sulfonamide (6) and reacted with either the piperidine hydrochloride (4) or the piperazine hydrochloride (12) (generically represented by V), respectively, the (sulfonylamino)-carboxylic acids (26) and (27) can be prepared, respectively. When in the procedures described for Schemes III and IV the (sulfonylamino)-carboxylic acids (26) and (27) are substituted for the (sulfonylamino)-carboxylic acids (7) or (13) and the appropriate methodology for either the piperidines (Scheme III) or piperazines (Scheme IV) is followed, the compounds (28) and (29) can be prepared, respectively.

SCHEME V



-37-

SCHEME V (Continued)



-38-

Compounds of Formula I wherein $z = n = 0$, R^1 is hydrogen, and Ar, m, Y, R^2 , R^3 , and R^4 are as defined in Formula I, can be synthesized according to the sequence described in Scheme VI below.


5 With regard to Scheme VI, an amine of formula R^2NH_2 , wherein R^2 is as defined in Formula I, is reacted with a bromo-ester (30), wherein R^3 is as defined in Formula I, in the presence of a suitable base such as triethylamine (Et_3N) or N,N-diisopropyl-N-ethylamine in a solvent such as diethyl ether or
10 tetrahydrofuran at temperatures between $-10^\circ C$ and $50^\circ C$ to afford the free amino ester which is converted to the amino ester hydrochloride (31). Alternatively, the amino ester hydrochloride (31) can be prepared by
15 reacting an alkyl halide of the formula R^2 -halo, wherein R^2 is as defined in Formula I and halo is defined as chlorine, bromine, or iodine, with an amino-ester hydrochloride (30a), wherein R^3 is as defined in Formula I, following the procedure described for (31).
20 The amino-ester hydrochloride (31) is reacted in a suitable aqueous acid mixture such as 6 M hydrochloric acid following the procedure described previously for Scheme V to yield the amino-acid hydrochloride (32). When in the procedure described for Scheme II the
25 amino-acid hydrochloride (32) is substituted for the amino acid (5) and reacted with 4-fluorobenzenesulfonyl chloride, the sulfonamide (33) is obtained. When in the procedures described for Schemes II and IV the sulfonamide (33) is substituted
30 for the sulfonamide (6) and reacted with either the piperidine hydrochloride (4) or the piperazine hydrochloride (12), respectively, the (sulfonylamino)-carboxylic acid (34) can be prepared. When in the procedures described for Schemes III and IV the
35 (sulfonylamino)-carboxylic acid (34) is substituted for either the (sulfonylamino)-carboxylic acid (7) or (13)

-39-

and the appropriate methodology for either the piperidines (Scheme III) or piperazines (Scheme IV) is followed, the compound (35) can be prepared, where R^4 is defined as $NHOR^9$ or NR^6R^{6a} .

-40-

SCHEME VI




-41-

Compounds of Formula I wherein $z = 0$, Ar, Y, m, n, R^1 , R^2 , and R^3 are as defined in Formula I, and R^4 is OH, can be synthesized according to the sequence described in Scheme VII below.

5 The commercially available fluorosulfonic acids (36) as their sodium salts are reacted with a suitable halogenating agent such as a mixture of phosphorus pentachloride (PCl_5) in phosphorus oxychloride ($POCl_3$) at temperatures between $-20^\circ C$ and $50^\circ C$ to yield the
10 sulfonyl chloride (37). The sulfonyl chloride (37) is reacted with either the amino acid (5) from Scheme II, the amino acid hydrochloride (21) from Scheme V, the amino acid hydrochloride (23) from Scheme V, or the amino acid hydrochloride (32) from Scheme VI, all of
15 which may be represented by the general structure designated by Formula III of Scheme I, in the presence of a suitable base such as triethylamine, sodium carbonate or potassium carbonate in a suitable solvent such as water, methanol, tetrahydrofuran or some
20 combination thereof, at temperatures between $0^\circ C$ and $50^\circ C$ to give the (sulfonylamino)-carboxylic acid (38). When in the procedures described for Schemes II and IV the sulfonamide (38) is substituted for the sulfonamide (6) and reacted with either the piperidine
25 hydrochloride (4) or the piperazine hydrochloride (12), respectively, represented by the general structure V, the (sulfonylamino)-carboxylic acid (40) can be prepared. When in the procedures described for
30 Schemes III and IV the (sulfonylamino)-carboxylic acid (40) is substituted for either the (sulfonylamino)-carboxylic acid (7) or (13) and the appropriate methodology for either the piperidines (Scheme III) or piperazines (Scheme IV) is followed, the compound (40a) can be prepared, where R^4 is defined as $NHOR^9$ or
35 NR^{6a} .

-42-

SCHEME VII



-43-

Compounds of Formula I wherein $z = 1$, R^1 is hydrogen, and Ar, Y, R^2 , R^3 , R^4 , W, m, and n are as defined in Formula I, can be prepared according to the sequence described in Scheme VIII.

5 With regard to Scheme VIII, the compound of Formula V is reacted with 4-fluorobenzoic acid, ethyl ester in the presence of an excess of a suitable base such as sodium carbonate (Na_2CO_3) or potassium carbonate in a suitable solvent such as dimethyl-
10 sulfoxide (DMSO) or dimethylformamide at temperatures between 25°C and 180°C to obtain the ester (41). The ester (41) is reduced with a suitable reducing agent such as lithium aluminum hydride ($LiAlH_4$) in a suitable solvent such as tetrahydrofuran at temperatures between
15 0°C and 60°C to yield the alcohol (42). The alcohol (42) is reacted with a suitable halogenating agent such as phosphorous tribromide (PBr_3) in dichloromethane at temperatures between -40°C and 40°C to yield the halide (43). The halide (43) is reacted with sodium
20 thiosulfate ($Na_2S_2O_3$) in water with or without a phase transfer agent such as N-methyl-N,N,N-tri(n-octyl)-ammonium chloride at temperatures between 0°C and 100°C in the presence of chlorine gas (Cl_2) to yield the sulfonyl chloride (44). Alternatively, the halide (43)
25 can be reacted with sodium thiosulfate ($Na_2S_2O_3$) in water with or without a phase transfer agent such as N-methyl-N,N,N-tri(n-octyl)ammonium chloride at temperatures between 25°C and 100°C to yield the sulfonate (45). The sulfonate (45) is then reacted
30 with a suitable halogenating agent such as a mixture of phosphorus pentachloride (PCl_5) in phosphorus oxychloride ($POCl_3$) at temperatures between -20°C and 150°C to yield the sulfonyl chloride (44). The sulfonyl chloride (44) is reacted with either the amino
35 acid (5) from Scheme II, the amino acid hydrochloride (21) from Scheme V, the amino acid hydrochloride (23)

-44-


from Scheme V, or the amino acid hydrochloride (32) from Scheme VI, all of which may be represented by the general structure designated by Formula III of Scheme I, in the presence of a suitable base such as triethylamine, sodium carbonate or potassium carbonate in a suitable solvent such as water, methanol, tetrahydrofuran or some combination thereof, at temperatures between 0°C and 50°C to give the (sulfonylamino)-carboxylic acid (46). Alternatively, the sulfonyl chloride (44) can be reacted with tert-butylamine in a suitable solvent such as diethylether or tetrahydrofuran in the presence of excess base such as tert-butylamine or triethylamine to yield the sulfonamide (48). The sulfonamide (48) can be reacted with two equivalents of a strong base such as n-butyl lithium, sec-butyl lithium, or tert-butyl lithium in a suitable solvent such as tetrahydrofuran at temperatures between -78°C to +25°C, followed by the addition of an alkyl halide of the formula R^2 -halo, wherein R^2 is as defined in Formula I, and halo is defined as chlorine, bromine, or iodine, to yield the sulfonamide (49). The sulfonamide (49) can be reacted with a strong acid such as trifluoroacetic acid (TFA) either neat or in a suitable solvent such as dichloromethane to yield the sulfonamide (50). The sulfonamide (50) can be reacted with a suitable base such as sodium hydride (NaH) in tetrahydrofuran as solvent or sodium ethoxide in ethanol as solvent, followed by the addition of the bromoester (30), wherein R^3 is as defined in Formula I, to yield the (sulfonylamino)-ester (51). The (sulfonylamino)-ester (51) can be reacted with either lithium, sodium, or potassium hydroxide in a suitable solvent such as ethanol followed by acidification to yield the (sulfonylamino)-carboxylic acid (52).

-45-


When in the procedures described for Schemes III and IV, the (sulfonylamino)-carboxylic acids (46) or (52) is substituted for either the (sulfonylamino)-carboxylic acid (7) or (13) and the appropriate methodology for either the piperidines (Scheme III) or piperazines (Scheme IV) is followed, the compounds (47) and (53) can be prepared, where R^4 is defined as $NHOR^9$ or NR^6R^{6a} .

-46-

SCHEME VIII



SCHEME VIII (Continued)




-48-

The O-substituted-hydroxylamine hydrochlorides of the formula $\text{H}_2\text{NOR}^9 \cdot \text{HCl}$ can be purchased from commercial sources or prepared as set forth in Scheme IX.

-49-

SCHEME IX



10

15

20

25

30

35

-50-

EXAMPLE 1

[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid(a) (4-Fluoro-benzenesulfonylamino)-acetic acid

5 A mixture of 4-fluoro-benzenesulfonyl chloride (9.68 g, 0.497 mol), glycine (4.48 g, 0.0598 mol), and sodium carbonate (16.99 g, 0.160 mol) in water (60 mL) was stirred at room temperature for 42 hours. The mixture was carefully acidified to pH 8 to 9 with
10 concentrated hydrochloric acid, and washed 2 times with dichloromethane. The aqueous layer was acidified further to pH 2, and the resulting white suspension was extracted two times with ethyl acetate. The extracts
15 were combined, washed with saturated sodium chloride solution, and dried over magnesium sulfate. The dried solution was rotary evaporated to give a white solid, which was dried in vacuo; yield 4.7 g (41%), mp = 154.0-155.5°C.

20 (b) [4-(4-Phenyl-piperidin-1-yl)benzenesulfonyl-amino] acetic acid

 A stirred mixture of (4-fluoro-benzenesulfonyl-amino)-acetic acid (0.0895 g, 0.000384 mol), 4-phenyl-piperidine (0.618 g, 0.000383 mol), and potassium
25 carbonate (0.109 g, 0.000789 mol) in dry dimethyl sulfoxide (0.10 mL) in a tightly capped vial was placed in a hot sand bath (115°C). After 21 hours, the reaction mixture was cooled and partitioned between ethyl acetate and water. The mixture was acidified
30 with 1M hydrochloric acid (3.2 mL, 0.0032 mol) and the layers were separated. The aqueous layer was washed with additional ethyl acetate. The organics were combined, dried (MgSO₄), and rotary evaporated to give a glass. The glass was dissolved in methanol, silica
35 gel was added (4.2 g, 230-400 mesh), and the mixture was rotary evaporated to dryness. The resulting powder

-51-

was poured onto a column of silica gel (14 g, 230-400 mesh), and eluted with a mixture of hexanes-ethyl acetate-acetic acid (15:15:1, 11 x 15 mL). Fractions containing product were combined and rotary evaporated. The residue was crystallized from methanol-water (1:1) after a hot filtration to give the title compound as a pale yellow solid; yield 0.070 g (49%), mp = 154.5-155.5°C.

EXAMPLE 2

N-Hydroxy-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetamide

(a) N-[(Phenylmethyl)oxyl]-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetamide

A suspension of O-benzylhydroxylamine hydrochloride (0.110 g, 0.000689 mol) in a mixture of triethylamine (0.096 mL, 0.00069 mol) in anhydrous tetrahydrofuran (7 mL) was heated on a steam bath, and dimethylformamide (=5 mL) was added until all solids had dissolved. The mixture was cooled to room temperature. The solids which precipitated were filtered off and set aside.

In a separate flask containing a cool (5°C), stirred solution of [4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid (0.2307 g, 0.0006161 mol) and 1-hydroxy-benzo-1,2,3-triazole (0.0842 g, 0.000623 mol) in anhydrous tetrahydrofuran (10 mL) was added in one portion 1,3-dicyclohexylcarbodiimide (0.1449 g, 0.000702 mol). The mixture was stirred for 30 minutes at 5°C then allowed to warm to room temperature. After 3 hours at room temperature, the mixture was added in one portion to the filtrate containing O-benzylhydroxylamine. The mixture was stirred at room temperature for 16 hours, then refluxed (74°C) for 1 hour. The volatiles were rotary evaporated off, and the residue was partitioned between

-52-

ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The organics were combined, washed with 0.1 M NaOH, water, 0.1 M HCl, water, and saturated sodium chloride. The organic layer was dried (MgSO₄) and rotary evaporated. The residue was dissolved in chloroform, and chromatographed on silica gel (34 g, 230-400 mesh) eluting with dichloromethane-acetone (9:1, 10 x 30 mL). Fractions containing product were rotary evaporated to give a white solid. The solid was dried in vacuo; yield 0.1448 g (49%), mp = 163-165°C.

(b) N-Hydroxy-2-[4-(4-phenyl-piperidin-1-yl)-benzene-sulfonylamino]-acetamide

A room temperature mixture of N-[phenyl-methyl]-oxy]-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetamide (0.1115 g, 0.0002325 mol) in methanol-tetrahydrofuran (1:1, 25 mL) was hydrogenated at 50 p.s.i. over 5% palladium on barium sulfate (0.018 g) for approximately 10 hours. Additional catalyst (0.020 g) was added, and the mixture hydrogenated again for approximately 10 hours. The mixture was filtered through celite, and the filtrate was rotary evaporated to give a glaze. The glaze was dissolved in chloroform-methanol, silica gel (1.6 g, 230-400 mesh) was added, and the mixture was rotary evaporated to dryness. The powder was poured onto a column of silica gel (10 g, 230-400 mesh) and eluted with hexanes-ethyl acetate-acetic acid (10:20:1, 16 x 10 mL and 10:20:2, 16x10 mL). Fractions containing product were rotary evaporated, and the residue triturated with chloroform. The chloroform suspension was filtered, and the filtercake was dried in vacuo; yield 0.0054 g (6.0%), mp = 164-166°C.

-53-

EXAMPLE 3

3-[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid(a) 3-[4-Fluoro-(benzenesulfonylamino)]-propionic acid, sodium salt

5 A mixture of 4-fluoro-benzenesulfonyl chloride (1.920 g, 0.009866 mol), 3-amino-propionic acid (0.980 g, 0.0110 mol), and sodium carbonate (2.33 g, 0.0220 mol) in water (15 mL) was stirred at room
10 temperature for 28 hours, then briefly heated on a steam bath. The mixture was allowed to cool, then stirred at room temperature overnight. The mixture was reheated on a steam bath, gravity filtered hot, and allowed to cool. The filtrate was acidified to
15 approximately pH 5 with concentrated hydrochloric acid. A white precipitate was filtered off and dried in vacuo; yield 1.907 g (78%).

¹H-NMR (DMSO-d₆): δ 7.85 (m, 2H), 7.80 (br s, 1H), 7.45 (m, 2H), 2.93 (t, 2H), 2.35 (t, 2H).

(b) 3-[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonyl-aminol-propionic acid

20 A stirred mixture of 3-[4-fluoro-(benzenesulfonyl amino)]-propionic acid, sodium salt (0.248 g, 0.00100 mol), 4-phenyl-piperidine hydrochloride (0.218 g, 0.00110 mol), and sodium carbonate (0.317 g, 0.00299 mol) in dry dimethyl sulfoxide (3 mL) was heated in a sand bath (130°C) under nitrogen for
25 22 hours. The mixture was cooled and partitioned between ethyl acetate and 1 M hydrochloric acid. The aqueous layer was extracted with additional ethyl acetate. The organics were combined, washed with saturated sodium chloride, dried (MgSO₄), and rotary evaporated. The residue was dissolved in dichloro-
30 methane and chromatographed on silica gel (14 g, 230-400 mesh) eluting with dichloromethane-methanol
35

-54-

(15:1, 10X15 mL). Fractions containing product were combined, rotary evaporated and rechromatographed to give the title compound as a peach-colored solid; yield 0.082 g (21%), mp = 145-147°C.

5

EXAMPLE 4

(R)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzene-sulfonylamino]-pentanoic acid

10 (a) (R)-2-(4-Fluoro-benzenesulfonylamino)-4-methyl-pentanoic acid

A mixture of 4-fluoro-benzenesulfonyl chloride (1.65 g, 0.00848 mol), (R)-2-amino-4-methyl-pentanoic acid (1.233 g, 0.009398 mol), and sodium carbonate (1.91 g, 0.0180 mol) in water (15 mL) was stirred at room temperature for 5 days. The solution was filtered, and the filtrate was acidified with concentrated hydrochloric acid to pH = 4. The mixture was extracted with ethyl acetate. The extract was washed with saturated sodium chloride, dried (MgSO₄), and rotary evaporated to a yellow oil. The oil was chromatographed on silica gel (320 g, 230-400 mesh) eluting with dichloromethane-methanol (10:1, 10X300 mL). Fractions containing product were combined and rotary evaporated to give a pale yellow oil. The oil was dried in vacuo; yield 1.44 g (59%).
25 ¹H-NMR (DMSO-d₆): δ 8.1 (br s, 1H), 7.80 (m, 2H), 7.38 (m, 2H), 3.55 (t, 1H), 3.33 (br s, H₂O), 1.56 (m, 1H), 1.36 (dd, 2H), 0.75 (dd, 6H).

30 (b) (R)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid

In a manner similar to Example 3(b), 4-phenyl-piperidine hydrochloride was condensed with (R)-2-(4-fluoro-benzenesulfonylamino)-4-methyl-pentanoic acid to give the title compound, mp = 163-165°C.

35

-55-

EXAMPLE 5

(S)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzene-sulfonylamino]-pentanoic acid

(a) (S)-2-(4-Fluoro-benzenesulfonylamino)-4-methyl-pentanoic acid

In a manner similar to Example 4(a) (S)-2-amino-4-methyl-pentanoic acid was substituted for (R)-2-amino-4-methyl-pentanoic acid; yield 14.0 g (55%).

300 MHz ¹H-NMR (DMSO-d₆): δ 8.17 (br s, 1H), 7.83 (m, 2H), 7.40 (m, 2H), 3.64 (t, 1H), 1.57 (m, 1H), 1.38 (m, 2H), 0.76 (dd, 6H).

(b) (S)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid

In a manner similar to Example 3(b), 4-phenyl-piperidine hydrochloride was condensed with (S)-2-(4-fluoro-benzenesulfonylamino)-4-methyl-pentanoic acid to give the title compound, %C,H,N found: 63.96, 6.96, 6.44.

EXAMPLE 6

(S)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzene-sulfonylamino]-propionic acid

(a) (S)-2-(4-Fluoro-benzenesulfonylamino)-3-phenyl-propionic acid, sodium salt

In a manner similar to Example 4(a), 4-fluoro-benzenesulfonyl chloride and (S)-2-amino-3-phenyl-propionic acid were condensed to give the title compound as a white solid, mp = 108-111°C.

(b) (S)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid

In a manner similar to Example 3(b), (S)-2-(4-fluoro-benzenesulfonylamino)-3-phenyl-propionic acid, sodium salt and 4-phenyl-piperidine hydrochloride were condensed to give the title compound, mp = 167-169°C.

-56-

EXAMPLE 7

(R)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid

- 5 (a) (R)-2-(4-Fluoro-benzenesulfonylamino)-3-phenyl-propionic acid, disodium salt

In a manner to Example 4(a), (R)-2-amino-3-phenyl-propionic acid was condensed with 4-fluoro-benzenesulfonyl chloride to give the title compound, mp = 246-248°C.

10

- (b) (R)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid

15 In a manner similar to Example 3(b), (R)-2-(4-fluoro-benzenesulfonylamino)-3-phenyl-propionic acid, disodium salt was condensed with 4-phenyl-piperidine hydrochloride to give the title compound, mp = 168-170°C.

EXAMPLE 8

- 20 (S)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid

- (a) (S)-2-(4-Fluoro-benzenesulfonylamino)-3-(1H-Indol-3-yl)-propionic acid

25 In a manner to Example 4 (a), 4-fluoro-benzenesulfonyl chloride was condensed with (S)-2-amino-3-(1H-Indol-3-yl)-propionic acid to give the title compound, mp = 57-60°C.

- 30 (b) (S)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid

In a manner similar to Example 3(b), (S)-2-(4-fluoro-benzenesulfonylamino)-3-(1H-Indol-3-yl)-propionic acid was condensed with 4-phenyl-piperidine hydrochloride to give the title compound, mp = 103-107°C.

35

-57-

EXAMPLE 9

(±)-5-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzene
sulfonylamino]-pentanoic acid

(a) (±)-2-Amino-5-phenyl-pentanoic acid

5 A stirred suspension of (±)-2-(acetylamino)-5-phenyl-pentanoic acid (0.5003 g, 0.002126 mol) in 2.8 M hydrochloric acid was refluxed for 2 hours, and the resulting brown solution was allowed to cool. A tan precipitate formed upon cooling. The solids were
10 filtered off, and the filtrate was rotary evaporated to give a yellow gum. The gum was dissolved in hot water, gravity filtered, and allowed to cool. The mixture was made basic with 1 M sodium hydroxide to pH = 5. The resulting precipitate was filtered off, washed with
15 water, and dried in vacuo to give a yellow solid; yield 0.205 g (50%), mp = 213-215°C.

(b) (±)-2-(4-Fluoro-benzenesulfonylamino)-5-phenyl-pentanoic acid

20 A mixture of (±)-2-amino-5-phenyl-pentanoic acid (0.188 g, 0.000973 mol), 4-fluoro-benzenesulfonyl chloride (0.189 g, 0.000971 mol), and sodium carbonate (0.208 g, 0.00196 mol) in water (4 mL) was stirred at room temperature for 4 days. The mixture was heated
25 briefly on a steam bath to give a cloudy solution. The solution was gravity filtered hot, and the filtrate allowed to cool. The resulting solid that crystallized was filtered off, washed with water, and dried in vacuo; yield 0.131 g, (38%). ¹H-NMR (DMSO-d₆):
30 δ 7.81 (m, 2H), 7.37 (t, 2H), 7.25 (t, 2H), 7.14 (m, 4H), 3.34 (br s, H₂), 3.04 (t, 1H), 2.46 (m, 2H), 1.6-1.4 (m, 4H).

-58-

(c) (±)-5-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid

5 In a manner similar to Example 3(b), (±)-2-(4-fluoro-benzenesulfonylamino)-5-phenyl-pentanoic acid was condensed with 4-phenyl-piperidine hydrochloride to give the title compound, mp = 59-62°C.

EXAMPLE 10

10 [4-(4-Phenyl-piperazin-1-yl)-benzenesulfonylamino]-acetic acid

In a manner similar to Example 3(b), (4-fluoro-benzenesulfonylamino)-acetic acid was condensed with 4-phenyl-piperazine to give the title compound, mp = 120-124°C.

15

EXAMPLE 11

(Isobutyl-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid

20 (a) Isobutylamino-acetic acid, ethyl ester hydrochloride

A mixture of isobutylamine (0.90 mL, 0.0091 mol), bromoacetic acid, ethyl ester (1.0 mL, 0.0090 mol), and triethylamine (1.28 mL, 0.00918 mol) in diethylether (15 mL) was stirred at room temperature for 24 hours. The resulting suspension was filtered off and washed with diethylether. The filtrate and washings were combined and rotary evaporated to an oil. The oil was chromatographed on silica gel (150 g, 230-400 mesh) eluting with dichloromethane-diethylether (19:1, 8 × 125 mL; 15:1, 7 × 125 mL; 10:1, 15 × 125 mL). Fractions containing product were combined and rotary evaporated to give an oil. The oil was dissolved in diethylether, concentrated hydrochloric acid (0.52 mL, 0.0063 mol HCl) was added, and the volatiles were rotary evaporated to give a white solid. The solid was dried in vacuo; yield 1.0 g (59%).

-59-

$^1\text{H-NMR}$ (DMSO-d_6): δ 9.23 (br s, 2H), 4.22 (q, 2H), 3.96 (m, 2H), 3.41 (br s, H_2O), 2.78 (m, 2H), 2.00 (m, 1H), 1.25 (t, 3H), 0.94 (d, 6H).

5 (b) [(4-Fluoro-benzenesulfonyl)-isobutyl-aminol]-acetic acid

A mixture of isobutylamino-acetic acid, ethyl ester hydrochloride (0.359 g, 0.00183 mol) in 6 M hydrochloric acid (10 mL) was refluxed for 20 hours and
10 allowed to cool. The mixture was made basic with 50% wt/wt sodium hydroxide and 1 M sodium hydroxide to pH = 5, and the volatiles were rotary evaporated. The residue was triturated 3 times with boiling methanol, and the triturates were combined and rotary evaporated.
15 The residue was triturated 3 times with hot acetic acid, and the triturates were combined and rotary evaporated. The residue was dissolved in water and freeze-dried to give a white solid. This solid was combined with 4-fluoro-benzenesulfonyl chloride
20 (0.3334 g, 0.001713 mol) and sodium carbonate (0.547 g, 0.00516 mol) in water, and the mixture was stirred at room temperature for 3 days. The mixture was acidified with concentrated hydrochloric acid and extracted with ethyl acetate. The extract was dried (MgSO_4) and
25 rotary evaporated to a white solid. The solid was chromatographed on silica gel (15 g, 230-400 mesh) eluting with dichloromethane-methanol (10:1, 10 x 15 mL). Fractions containing product were combined and rotary evaporated to give a white solid. The solid was
30 dried in vacuo; yield 0.32 g (64% overall).
 $^1\text{H-NMR}$ (DMSO-d_6): δ 7.85 (m, 2H), 7.39 (m, 2H), 3.91 (s, 2H), 3.32 (br s, H_2O), 2.94 (d, 2H), 1.77 (m, 1H), 0.79 (d, 6H).

-60-

(c) {Isobutyl-[4-(4-phenyl-piperidin-1-yl)-benzene-sulfonylamino]-acetic acid

In a manner similar to Example 3(b), [(4-fluoro-benzenesulfonyl)-isobutyl-amino]-acetic acid was
5 condensed with 4-phenyl-piperidine hydrochloride to give the title compound, mp = 140-143°C.

EXAMPLE 12

10 (S)-2-[4-(4-Benzyl-piperidin-1-yl)-benzenesulfonyl-aminol]-3-phenyl-propionic acid

In a manner similar to Example 3(b), (S)-2-(4-fluoro-benzenesulfonylamino)-3-phenyl-propionic acid, sodium salt, and 4-benzyl-piperidine were condensed to give the title compound, mp = 164-165°C.

15

EXAMPLE 13

(S)-3-(4-Benzoyloxy-phenyl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid

20 (a) (S)-3-(4-Benzoyloxy-phenyl)-2-(4-fluoro-benzene-sulfonylamino)-propionic acid

A mixture of (S)-2-amino-3-(4-benzoyloxy-phenyl)-propionic acid (2.7 g, 0.010 mol), 4-fluoro-benzene-sulfonyl chloride (2.0 g, 0.010 mol), and sodium carbonate (2.2 g, 0.020 mol) in a mixture of tetrahydrofuran (20 mL) and water (20 mL) was stirred at
25 room temperature for 3 days. The reaction mixture was partitioned between ethyl acetate and 1 M hydrochloric acid. The organic layer was washed with saturated sodium chloride solution, dried (MgSO₄), and rotary-evaporated under reduced pressure to give an oil. The
30 oil was chromatographed on silica gel (445 g, 230-400 mesh) eluting with dichloromethane-methanol (20:1), and the fractions containing product were rotary-evaporated to give a solid. The solid was
35 recrystallized from toluene to give the title compound

-61-

as a light yellow solid; yield 0.22 g (5%),
mp = 138-139°C.

5 (b) (S)-3-(4-Benzoyloxy-phenyl)-2-[4-(4-phenyl-
piperidin-1-yl)-benzenesulfonylamino]-propionic
acid

In a manner similar to Example 3(b), (S)-3-
(4-benzoyloxy-phenyl)-2-(4-fluoro-benzenesulfonylamino)-
propionic acid was condensed with 4-phenyl-piperidine
10 hydrochloride to give the title compound, mp = 75-78°C.

EXAMPLE 14

(S)-3-(4-Hydroxy-phenyl)-2-[4-(4-phenyl-piperidin-
1-yl)-benzenesulfonylamino]-propionic acid

15 To a room temperature, stirred mixture of
(S)-3-(4-benzoyloxy-phenyl)-2-[4-(4-phenyl-piperidin-
1-yl)-benzenesulfonylamino]-propionic acid (0.033 g,
0.000058 mol) in thioanisole (0.34 mL) was added
trifluoroacetic acid (1 mL), and the mixture was
20 stirred for 18 hours. The reaction mixture was poured
into water and extracted with ethyl acetate. The
organic layer was dried (Na₂SO₄) and rotary-evaporated
under reduced pressure to remove volatiles. The
resulting yellow solution was chromatographed on silica
25 gel (5.5 g) eluting with dichloromethane (10 × 5 mL)
followed by dichloromethane-methanol (14:1). Fractions
containing product were rotary-evaporated. The residue
was suspended in water and stirred to give the title
compound as an off-white solid; yield 0.0079 g (28%),
30 mp = 108-110°C.

EXAMPLE 15

(S)-3-Phenyl-2-[4-(4-phenyl-piperazin-1-yl)-benzene-
sulfonylamino]-propionic acid

35 In a manner similar to Example 3(b), (S)-2-
(4-fluoro-benzenesulfonylamino)-propionic acid, sodium

-62-

salt and 4-phenyl-piperazine were condensed to give the title compound as a beige solid, mp = 192-193°C.

EXAMPLE 16

5 (S)-2-{4-[-4-(3-Methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino}-3-phenyl-propionic acid

 In a manner similar to Example 3(b), (S)-2-(4-fluoro-benzenesulfonylamino)-propionic acid, sodium salt and 4-(3-methoxy-phenyl)-piperazine were condensed
10 to give the title compound as a pale red-brown solid, mp = 137-139°C.

EXAMPLE 17

15 (S)-2-{4-[-4-(3-Hydroxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino}-3-phenyl-propionic acid hydrobromide

 To a stirred suspension of (S)-2-{4-[4-(3-methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino}-3-phenyl-propionic acid (0.103 g, 0.000208 mol) in dichloromethane (2 mL) at -78°C under nitrogen was added
20 dropwise a 1.0 M solution of boron tribromide in dichloromethane (1.0 mL, 0.0010 mol). The mixture was stirred for 15 minutes at -78°C and then allowed to warm to +3°C. After 6 hours, the reaction mixture was
25 diluted with water. The resulting suspension was stirred overnight. The solids were filtered off, washed with additional water, and dried in vacuo to give the title compound as an off-white solid; yield
30 0.069 g (69%), mp = 229-230°C.

EXAMPLE 18

(S)-2-{4-[-4-(4-Methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino}-3-phenyl-propionic acid

 In a manner similar to Example 3(b), (S)-2-(4-fluoro-benzenesulfonylamino)-propionic acid, sodium salt and 4-(4-methoxy-phenyl)-piperazine dihydro-
35

-63-

chloride were condensed to give the title compound as a brown solid, mp = 203-205°C.

INHIBITION STUDIES

- 5 Experiments were carried out which demonstrate the efficacy of compounds of Formula I as potent inhibitors of stromelysin-1 and gelatinase A. Experiments were carried out with the catalytic domains. Table 1 shows the activity of the Examples 1-12 versus GCD
- 10 (recombinant gelatinase A catalytic domain); SCD (stromelysin-1 catalytic domain). IC₅₀ values were determined using a thiopeptolide substrate, Ac-Pro-Leu-Gly-thioester-Leu-Leu-Gly-OEt (Ye Q.-Z., Johnson L.L., Hupe D.J. and Baragi V., "Purification and
- 15 Characterization of the Human Stromelysin Catalytic Domain Expressed in *Escherichia coli*", Biochemistry, 1992;31:11231-11235).

-64-


TABLE 1

| | Compound Number | IC ₅₀ μ M/SCD | IC ₅₀ μ M/GCD |
|----|--------------------|------------------------------|------------------------------|
| | 1 | 0.02 | 0.21 |
| 5 | 2 | 0.019 | 0.81 |
| | 3 | 1.24 | 4.8 |
| | 4 | 0.036 | 0.93 |
| | 5 | 0.011 | 0.084 |
| | 6 | 0.014 | 0.22 |
| 10 | 7 | 0.012 | 0.12 |
| | 8 | 0.01 | 0.32 |
| | 9 | 0.30 | 0.40 |
| | 10 | 0.05 | 0.50 |
| | 11 | 0.17 | 3.3 |
| 15 | 12 | 0.60 | 3.2 |
| | 13 | 0.19 | 5.3 |
| | 14 | 0.015 | 0.13 |
| | 15 | 0.021 | 0.088 |
| | 16 | 0.062 | 0.33 |
| 20 | 17 | 0.077 | 0.18 |
| | 18 | 0.014 | 0.033 |

-65-

CLAIMS

1. A compound of the Formula I



wherein:

- 10 Ar is selected from phenyl;
phenyl substituted with alkyl, -NO₂, halogen,
-OR⁵, -CN, -CO₂R⁵, -SO₃R⁵, -CHO, -COR⁵,
-CONHR⁵, -NHR⁵, or -NHCOR⁵;
heteroaryl; or
15 2-naphthyl;
R¹ is hydrogen, methyl, -NO₂, -Cl, -NH₂,
-NHCO₂CH₃, -OH, or -CO₂H;
R² and R³ are the same or different and are
independently selected from hydrogen, alkyl,
20 -(CH₂)_v-aryl, -(CH₂)_v-heteroaryl,
-(CH₂)_v-cycloalkyl, -(CH₂)_p-X-(CH₂)_q-aryl,
-(CH₂)_p-X-(CH₂)_q-heteroaryl, -(CH₂)_tNR⁶R^{6a},
-(CH₂)_vR⁷, -(CH₂)_vCO₂R⁵, -(CH₂)_vCONR⁶R^{6a}, or
-(CH₂)_vSR⁵;
25 m is zero or 1;
Y is CH or N; provided that when m = 1, Y does
not = N;
z is zero or 1;
z is zero or 1;
30 W is -CHR⁸;
n is zero or 1;
R⁴ is -OH, -NR⁶R^{6a}, or -NHOR⁹;
R⁵ is hydrogen or alkyl;
v is 1 to 5;
35 X is O or S;

-66-

- p and q are independently 1 to 5, provided that
p+q is not greater than 5;
t is 1 to 9;
R⁶ and R^{6a} are each the same or different and are
5 hydrogen or alkyl;
R⁷ is 1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl, or
1,3-dihydro-1,3-dioxo-benzo[f]isoindol-2-yl;
R⁸ is hydrogen or alkyl; and
R⁹ is hydrogen, alkyl, or benzyl; or
10 a pharmaceutically acceptable salt thereof.
2. A compound of Claim 1 wherein:
Ar is phenyl;
m is 0 or 1;
Y is CH or N; provided that when m = 1, Y does
5 not = N;
z is zero or 1;
R¹ is hydrogen;
Z is zero;
R² is hydrogen or alkyl;
10 R³ is hydrogen, alkyl, -(CH₂)_n-aryl, or
-(CH₂)_n-heteroaryl;
R⁴ is -OH or -NHOH;
n is 0 or 1; and
W is -CH₂-; or
15 a pharmaceutically acceptable salt thereof.
3. A compound of Claim 1 wherein Z is zero, or a
pharmaceutically acceptable salt thereof.
4. A compound of Claim 1 wherein Ar is phenyl, or a
pharmaceutically acceptable salt thereof.
5. A compound of Claim 1 wherein Y is N, or a
pharmaceutically acceptable salt thereof, provided
that m = 0.

-67-

6. A compound of Claim 1 wherein m is zero, or a pharmaceutically acceptable salt thereof.
7. A compound of Claim 1 wherein R² is hydrogen, or a pharmaceutically acceptable salt thereof.
8. A compound of Claim 1 wherein R¹ is hydrogen, or a pharmaceutically acceptable salt thereof.
9. A compound of Claim 1 wherein n is zero, or a pharmaceutically acceptable salt thereof.
10. A compound of Claim 1 wherein R⁴ is -OH.
11. A compound of Claim 1 that is
 - [4-(4-Phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid;
 - N-Hydroxy-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetamide;
 - 5 3-[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;
 - (R)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid;
 - 10 (S)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid;
 - (S)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;
 - (R)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;
 - 15 (S)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;
 - (±)-5-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid;
 - 20 [4-(4-Phenyl-piperazin-1-yl)-benzenesulfonylamino]-acetic acid;

-68-

- {Isobutyl-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonyl]amino}-acetic acid;
- 25 (S)-4-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-butyric acid;
- (R)-2-[4-(4-Phenyl-piperidin-1-yl)-benzenesulfonylamino]-3-tritylsulfanyl-propionic acid, sodium salt;
- 30 (R)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid, disodium salt, monohydrate;
- (S)-2-[4-[-4-(4-Hydroxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid;
- 35 (S)-2-[4-[-4-(4-Chloro-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid, hydrochloride;
- (R)-3-Mercapto-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid, trifluoroacetic acid salt;
- 40 (S)-2-[4-(4-Benzyl-piperidin-1-yl)-benzenesulfonylamino]-3-phenyl-propionic acid;
- (S)-3-(4-Benzoyloxy-phenyl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;
- 45 (S)-3-(4-Hydroxy-phenyl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;
- 50 (S)-3-Phenyl-2-[4-(4-phenyl-piperazin-1-yl)-benzenesulfonylamino]-propionic acid;
- (S)-2-[4-[-4-(3-Methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid;
- (S)-2-[4-[-4-(3-Hydroxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino]-3-phenyl-propionic acid hydrobromide; and
- 55

-69-

(S)-2-{4-[-4-(4-Methoxy-phenyl)-piperazin-1-yl]-benzenesulfonylamino}-3-phenyl-propionic acid.

12. A compound of Claim 1 that is

(R)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid;

5 (S)-4-Methyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-pentanoic acid;

(S)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid;

(R)-3-Phenyl-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid; and

10 (S)-3-(1H-Indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid.

13. A method of inhibiting a matrix metalloproteinase, the method comprising administering to a patient in need of matrix metalloproteinase inhibition a matrix metalloproteinase inhibiting amount of a
5 compound of Claim 1.

14. The method of Claim 13 wherein the matrix metalloproteinase is stromelysin-1.

15. The method of Claim 13 wherein the matrix metalloproteinase is gelatinase-A.

16. A method of preventing atherosclerotic plaque rupture comprising administering to a patient suffering from an atherosclerotic plaque a therapeutically effective amount of a compound of
5 Claim 1.

-70-

17. A method of inhibiting aortic aneurism comprising administering to a patient having an aortic aneurism a therapeutically effective amount of a compound of Claim 1.
18. A method of preventing restenosis comprising administering to a patient following balloon angioplasty, graft or shunt implantation or atherectomy, a therapeutically effective amount of
5 a compound of Claim 1.
19. A method of treating periodontal disease comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.
20. A method of treating burns comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.
21. A method of treating decubital ulcers comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.
22. A method of treating chronic ulcers or wounds comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.
23. A method of treating cancer comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.

-71-

24. A method of treating arthritis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.
25. A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a patient suffering from an autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes a therapeutically effective amount of a compound of Claim 1.
26. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
27. A method of treating multiple sclerosis comprising administering to a patient suffering therefrom a therapeutically effective amount of a compound of Claim 1.

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 96/16761

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D295/08 A61K31/495 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | EP,A,0 139 947 (HOECHST AKTIENGESELLSCHAFT) 8 May 1985 see page 14 - page 16; claims --- | 1,2 |
| A | EP,A,0 602 878 (ELI LILLY AND COMPANY) 22 June 1994 see the whole document --- | 1-27 |
| A | JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 9, September 1990, pages 2393-2407, XP002020347 J.J. HOWBERT ET AL: see page 2395, column 1 ----- | 1-27 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

28 January 1997

Date of mailing of the international search report

05.02.1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 16761

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13-27 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 96/16761

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date | |
|---|---------------------|----------------------------|---------------------|----------|
| EP-A-139947 | 08-05-85 | DE-A- | 3330603 | 21-03-85 |
| | | CA-A- | 1231709 | 19-01-88 |
| | | DE-A- | 3473270 | 15-09-88 |
| | | JP-B- | 4042379 | 13-07-92 |
| | | JP-A- | 60072853 | 24-04-85 |
| | | US-A- | 4725679 | 16-02-88 |
| ----- | | | | |
| EP-A-602878 | 22-06-94 | CA-A- | 2110524 | 11-06-94 |
| | | JP-A- | 6211777 | 02-08-94 |
| | | US-A- | 5565494 | 15-10-96 |
| ----- | | | | |